FDA Advises Companies To Pay Close Attention to Raw Materials In Cell Therapy Manufacture
FDA officials attempt to clear up questions on regulatory expectations for qualifying raw materials for cell and gene therapy products. FDA officials advise manufacturers to conduct risk assessments, use the highest-grade materials they can find and avoid using animal-derived raw materials. Industry officials describe complexities in making these products.
You may also be interested in...
Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.
Other CAR-T sponsors can only hope for the same kind of US FDA advisory committee success that Novartis enjoyed with tisagenlecleucel, an outcome that reflected the sponsor's experience and preparation, a lack of major show-stopping safety or product quality concerns, and robust efficacy in a narrow pediatric population.
Company prices Imlygic (T-VEC) cancer vaccine at the average cost of $65,000, aims to launch within a week.